Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.59 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.59 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.59 |
| ▸ | AGXT | P21549 | 1/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | GLS | O94925 | 2/20 | 0.49 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.49 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | PTGES | O14684 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.48 |
| ▸ | LOX | P28300 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL631264 | 0.84 | CYP2A6 (0.61) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL29534459 | 0.84 | CYP2A6 (0.61) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL1260041 | 0.82 | CYP2A6 (0.59) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL31356469 | 0.82 | CYP2A6 (0.59) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL11215245 | 0.82 | CYP2A6 (0.59) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL6674653 | 0.81 | CYP2A6 (0.58) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL11221971 | 0.81 | CYP2A6 (0.58) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL29861035 | 0.79 | CYP2A6 (0.56) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL28666644 | 0.79 | CYP2A6 (0.56) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL1177008 | 0.78 | CYP2A6 (0.58) | CYP2A6ASIC3LOXL2AGXTADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4761424-A | Enolamides, pharmaceutical compositions and methods for treating inflammation | WARNER-LAMBERT COMPANY (US) | 1988-08-02 | — | — | US | claimed |
| EP-0221345-A1 | Novel enolamides, process for their manufacture and pharmaceutical compositions thereof with an activity as modulators of the arachidonic acid cascade | WARNER-LAMBERT COMPANY (US) | 1987-05-13 | — | — | EP | claimed |
| EP-0168222-A2 | 3-(Alkynylalkyloxy) Cephalosporins | ELI LILLY AND COMPANY (US) | 1986-01-15 | — | — | EP | claimed |
| US-9642847-B2 | Combinational compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9447088-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150328208-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2015-11-19 | — | — | US | disclosed |
| EP-2451799-B1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-22 | — | — | EP | disclosed |
| US-20140200199-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. | 2014-07-17 | — | — | US | disclosed |
| US-8754078-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8486986-B2 | Microbiocides | SYNGENTA CROP PROTECTION LLC (US) | 2013-07-16 | — | — | US | disclosed |
| US-20030236232-A1 | Novel spla2 inhibitors | ELI LILLY AND COMPANY | 2003-12-25 | — | — | US | disclosed |
| US-4921871-A | LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1990-05-01 | — | — | US | disclosed |
| US-4874758-A | LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1989-10-17 | — | — | US | disclosed |
| US-4868195-A | ENZYME INHIBITORS, ANTIALLERGEN, ASTHMA, CARDIOVASCULAR, ANTIINFLAMMATORY | WARNER-LAMBERT COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4868200-A | LEUKOTRIENES, LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4868205-A | ANTIALLERGENS, ANTIINFLAMMATORY, CARDIOVASCULAR DISORDERS | WARNER-LAMBERT COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4868199-A | ENZYME INHIBITORS, ANTIALLERGEN, ASTHMA, CARDIOVASCULAR, ANTIINFLAMMATORY | WARNER-LAMBERT COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4761424-A | Enolamides, pharmaceutical compositions and methods for treating inflammation | WARNER-LAMBERT COMPANY (US) | 1988-08-02 | — | — | US | disclosed |
| EP-0221345-A1 | Novel enolamides, process for their manufacture and pharmaceutical compositions thereof with an activity as modulators of the arachidonic acid cascade | WARNER-LAMBERT COMPANY (US) | 1987-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236232-A1 | Novel spla2 inhibitors | PLA2G2E, PLA2G4B, PLA2G12A | CYP2A6 1690/4885ASIC3 3888/4885LOXL2 234/4885 |
| US-20150328208-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | TP53, MKI67, POLI | CYP2A6 4330/4885ASIC3 4778/4885LOXL2 2825/4885 |
| US-20140200199-A1 | Compositions and Methods for Treatment of Cancer | MKI67, NUP205, TP53 | CYP2A6 4120/4885ASIC3 4155/4885LOXL2 4073/4885 |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | MKI67, NUP205, TP53 | CYP2A6 4120/4885ASIC3 4155/4885LOXL2 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.